This Corifact market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth during the historic period can be attributed to the higher usage of factor XIII concentrates, increased awareness, greater automation, rising demand for extended care delivery, and the adoption of new plasma fractionation technologies.
Growth during the market's forecast period can be attributed to the rising prevalence of bleeding disorders, heightened awareness and early diagnosis, an increase in the number of surgical procedures, growing reliance from the client base, and the extended half-life of factor VIII. Key trends in the forecast period include technological advancements, improvements in healthcare infrastructure, innovative approaches to recombinant therapy development, progress in biotechnology, and the FDA approval of corifact.
The growing prevalence of bleeding disorders is expected to drive the growth of the corifact market in the future. Bleeding disorders are conditions that impair the blood's ability to form clots properly, resulting in prolonged or excessive bleeding. The increase in bleeding disorders is largely due to improved diagnostic techniques, greater awareness, advances in genetic testing, as well as lifestyle changes and the rising prevalence of underlying conditions. Corifact addresses bleeding disorders caused by factor XIII deficiency by replacing the missing clotting factor, facilitating stable blood clot formation, and reducing excessive bleeding. For example, a report published by the World Federation of Hemophilia in October 2023 revealed that in 2022, 427,685 individuals globally were diagnosed with bleeding disorders, which included 257,146 cases of hemophilia, 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. Therefore, the growing prevalence of bleeding disorders is fueling the growth of the corifact market.
The increasing demand for biological products is expected to drive the corifact market forward. Biological products are complex pharmaceutical substances derived from living organisms, used for diagnosing, preventing, treating, and curing diseases and medical conditions. The growing demand for these products is driven by factors such as environmental concerns, increased consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Corifact enhances the stability, bioavailability, and efficacy of biological products, ensuring optimal performance and extended shelf life through innovative formulation and delivery solutions. For instance, according to the US Food and Drug Administration, 40 biosimilars had been approved by the end of 2022, with 27 available in the United States. Therefore, the rising demand for biological products is supporting the growth of the corifact market.
The growing number of surgical procedures is also expected to drive the growth of the corifact market in the future. Surgical procedures are medical operations performed by healthcare professionals to treat injuries, diseases, or abnormalities through manual or instrumental methods. The rise in surgical procedures is mainly due to an aging population requiring treatment for age-related conditions, as well as advancements in minimally invasive technologies that make surgeries safer and more accessible. Corifact is used in surgical procedures to control excessive bleeding and support wound healing in patients with congenital Factor XIII deficiency by stabilizing blood clots. For example, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a trade association, plastic surgeons globally reported an 11.2% increase in procedures in 2022, with over 14.9 million surgical and 18.8 million non-surgical procedures performed worldwide. Liposuction remained the most common surgical procedure, with over 2.3 million procedures performed, a 21.1% increase from the previous year. Therefore, the rising number of surgical procedures is contributing to the growth of the corifact market.
The key company operating in the corifact market is CSL Behring.
North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in corifact report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the corifact market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Corifact is a fibrinogen concentrate used in medical treatments to manage bleeding, especially in patients with fibrinogen deficiency or low fibrinogen levels. This deficiency can occur in conditions such as trauma, surgery, or liver disease. Corifact helps to support blood clotting by supplying fibrinogen, a protein crucial for blood clot formation.
The primary product types in the corifact market are human-derived factor XIII and recombinant factor XIII. Human-derived Factor XIII (FXIII) is a protein that plays a key role in the final stages of blood clotting. The therapeutic applications of Corifact include routine prophylactic treatment and perioperative management. It is distributed through hospital pharmacies, specialty pharmacies, and outpatient clinics.
The corifact market research report is one of a series of new reports that provides corifact market statistics, including corifact industry global market size, regional shares, competitors with a corifact market share, detailed corifact market segments, market trends and opportunities, and any further data you may need to thrive in the corifact industry. This corifact market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The corifact market consists of sales of products including fibrinogen concentrates, factor concentrates, coagulation factor products, cryoprecipitate, and recombinant clotting factors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth during the historic period can be attributed to the higher usage of factor XIII concentrates, increased awareness, greater automation, rising demand for extended care delivery, and the adoption of new plasma fractionation technologies.
Growth during the market's forecast period can be attributed to the rising prevalence of bleeding disorders, heightened awareness and early diagnosis, an increase in the number of surgical procedures, growing reliance from the client base, and the extended half-life of factor VIII. Key trends in the forecast period include technological advancements, improvements in healthcare infrastructure, innovative approaches to recombinant therapy development, progress in biotechnology, and the FDA approval of corifact.
The growing prevalence of bleeding disorders is expected to drive the growth of the corifact market in the future. Bleeding disorders are conditions that impair the blood's ability to form clots properly, resulting in prolonged or excessive bleeding. The increase in bleeding disorders is largely due to improved diagnostic techniques, greater awareness, advances in genetic testing, as well as lifestyle changes and the rising prevalence of underlying conditions. Corifact addresses bleeding disorders caused by factor XIII deficiency by replacing the missing clotting factor, facilitating stable blood clot formation, and reducing excessive bleeding. For example, a report published by the World Federation of Hemophilia in October 2023 revealed that in 2022, 427,685 individuals globally were diagnosed with bleeding disorders, which included 257,146 cases of hemophilia, 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. Therefore, the growing prevalence of bleeding disorders is fueling the growth of the corifact market.
The increasing demand for biological products is expected to drive the corifact market forward. Biological products are complex pharmaceutical substances derived from living organisms, used for diagnosing, preventing, treating, and curing diseases and medical conditions. The growing demand for these products is driven by factors such as environmental concerns, increased consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Corifact enhances the stability, bioavailability, and efficacy of biological products, ensuring optimal performance and extended shelf life through innovative formulation and delivery solutions. For instance, according to the US Food and Drug Administration, 40 biosimilars had been approved by the end of 2022, with 27 available in the United States. Therefore, the rising demand for biological products is supporting the growth of the corifact market.
The growing number of surgical procedures is also expected to drive the growth of the corifact market in the future. Surgical procedures are medical operations performed by healthcare professionals to treat injuries, diseases, or abnormalities through manual or instrumental methods. The rise in surgical procedures is mainly due to an aging population requiring treatment for age-related conditions, as well as advancements in minimally invasive technologies that make surgeries safer and more accessible. Corifact is used in surgical procedures to control excessive bleeding and support wound healing in patients with congenital Factor XIII deficiency by stabilizing blood clots. For example, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a trade association, plastic surgeons globally reported an 11.2% increase in procedures in 2022, with over 14.9 million surgical and 18.8 million non-surgical procedures performed worldwide. Liposuction remained the most common surgical procedure, with over 2.3 million procedures performed, a 21.1% increase from the previous year. Therefore, the rising number of surgical procedures is contributing to the growth of the corifact market.
The key company operating in the corifact market is CSL Behring.
North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in corifact report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the corifact market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Corifact is a fibrinogen concentrate used in medical treatments to manage bleeding, especially in patients with fibrinogen deficiency or low fibrinogen levels. This deficiency can occur in conditions such as trauma, surgery, or liver disease. Corifact helps to support blood clotting by supplying fibrinogen, a protein crucial for blood clot formation.
The primary product types in the corifact market are human-derived factor XIII and recombinant factor XIII. Human-derived Factor XIII (FXIII) is a protein that plays a key role in the final stages of blood clotting. The therapeutic applications of Corifact include routine prophylactic treatment and perioperative management. It is distributed through hospital pharmacies, specialty pharmacies, and outpatient clinics.
The corifact market research report is one of a series of new reports that provides corifact market statistics, including corifact industry global market size, regional shares, competitors with a corifact market share, detailed corifact market segments, market trends and opportunities, and any further data you may need to thrive in the corifact industry. This corifact market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The corifact market consists of sales of products including fibrinogen concentrates, factor concentrates, coagulation factor products, cryoprecipitate, and recombinant clotting factors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Corifact Market Characteristics4. Corifact Market Trends and Strategies5. Corifact Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Corifact Pricing Analysis & Forecasts30. Global Corifact Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Corifact Market32. Recent Developments in the Corifact Market
3. Corifact Market Biologic Drug Characteristics
6. Global Corifact Growth Analysis and Strategic Analysis Framework
8. Corifact Market Segmentation
9. Global Corifact Epidemiology of Clinical Indications
10. Corifact Market Regional and Country Analysis
11. Asia-Pacific Corifact Market
12. China Corifact Market
13. India Corifact Market
14. Japan Corifact Market
15. Australia Corifact Market
16. South Korea Corifact Market
17. Western Europe Corifact Market
18. UK Corifact Market
19. Germany Corifact Market
20. France Corifact Market
21. Eastern Europe Corifact Market
22. North America Corifact Market
23. USA Corifact Market
24. Canada Corifact Market
25. South America Corifact Market
26. Middle East Corifact Market
27. Africa Corifact Market
28. Corifact Market Competitive Landscape and Company Profiles
29. Global Corifact Market Pipeline Analysis
33. Corifact Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Corifact Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on corifact market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for corifact? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The corifact market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product: Human-Derived Factor XIII; Recombinant Factor XII2) by Therapeutic Applications: Routine Prophylactic Treatment; Peri-Operative Management
3) by Distribution Channels: Hospital Pharmacies; Specialty Pharmacies; Outpatient Clinics
Key Companies Mentioned: CSL Behring
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- CSL Behring
